S. Atkinson

发表

Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.

P. Soden, N. Lamadema, Christopher J. Matthews, 2013, Journal of medicinal chemistry.

Structure-activity relationships of 1,5-biaryl pyrroles as EP1 receptor antagonists.

I. Chessell, A. Naylor, S. Atkinson, 2006, Bioorganic & medicinal chemistry letters.

Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation

David M. Wilson, G. Drewes, D. Eberhard, 2015, Nature chemical biology.

Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors.

P. Grandi, I. Wall, James M. Woolven, 2021, Journal of medicinal chemistry.

Discovery of novel, non-acidic 1,5-biaryl pyrrole EP1 receptor antagonists.

I. Chessell, A. Naylor, S. Atkinson, 2007, Bioorganic & medicinal chemistry letters.

Identification of a Series of N-Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) Proteins.

P. Grandi, A. Michon, I. Wall, 2021, Journal of medicinal chemistry.

The Optimisation of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode.

P. Bamborough, R. Prinjha, C. Chung, 2020, Journal of medicinal chemistry.

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation

P. Grandi, A. Michon, G. Drewes, 2020, Science.

A patent review of MAT2a inhibitors (2018–2021)

James S. Scott, S. Atkinson, L. Evans, 2022, Expert opinion on therapeutic patents.

Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors.

P. Grandi, I. Wall, James M. Woolven, 2021, Journal of medicinal chemistry.

Chan-Evans-Lam Amination of Boronic Acid Pinacol (BPin) Esters: Overcoming the Aryl Amine Problem.

Julien C. Vantourout, S. Atkinson, Albert Isidro-Llobet, 2016, The Journal of organic chemistry.

Total Synthesis of Aplyronine C

S. Atkinson, I. Paterson, S. Blakey, 2013, Organic letters.

The Optimisation of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor.

P. Grandi, A. Michon, I. Wall, 2020, Journal of medicinal chemistry.

Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.

N. Lamadema, Christopher J. Matthews, C. Marson, 2015, Journal of medicinal chemistry.

Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.

P. Bamborough, R. Prinjha, C. Chung, 2018, Journal of medicinal chemistry.

Alkene Oxyamination Using Malonoyl Peroxides: Preparation of Pyrrolidines and Isoxazolidines.

S. Atkinson, S. Lucas, A. Kennedy, 2018, The Journal of organic chemistry.

The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes

Kathryn A. Giblin, G. Drewes, M. Bantscheff, 2014 .

Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit.

P. Grandi, I. Wall, R. Prinjha, 2021, Journal of medicinal chemistry.

GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family.

P. Grandi, A. Michon, I. Wall, 2020, ACS Medicinal Chemistry Letters.

The Design and Synthesis of a Highly Selective and In Vivo Capable Inhibitor of the Second Bromodomain (BD2) of the Bromodomain and Extra Terminal Domain (BET) Family of Proteins.

P. Grandi, A. Michon, I. Wall, 2020, Journal of medicinal chemistry.

Design and Synthesis of a Highly Selective and In Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins

P. Grandi, A. Michon, James M. Woolven, 2020, Journal of Medicinal Chemistry.